William Ho - In8bio President, CoFounder
| INAB Stock | USD 0.31 0.01 3.33% |
Insider
William Ho is President, CoFounder of In8bio Inc
| Age | 45 |
| Address | 350 5th Avenue, New York, NY, United States, 10118 |
| Phone | 646 600 6438 |
| Web | https://in8bio.com |
William Ho Latest Insider Activity
Tracking and analyzing the buying and selling activities of William Ho against In8bio stock is an integral part of due diligence when investing in In8bio. William Ho insider activity provides valuable insight into whether In8bio is net buyers or sellers over its current business cycle. Note, In8bio insiders must abide by specific rules, including filing SEC forms every time they buy or sell In8bio'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
William Ho over a month ago Disposition of 81967 shares by William Ho of In8bio at 1.25 subject to Rule 16b-3 | ||
William Ho over three months ago Disposition of 5000 shares by William Ho of RAPT Therapeutics at 22.32 subject to Rule 16b-3 | ||
William Ho over three months ago Acquisition by William Ho of 56000 shares of RAPT Therapeutics at 29.05 subject to Rule 16b-3 | ||
William Ho over six months ago Acquisition by William Ho of 460 shares of RAPT Therapeutics at 12.0 subject to Rule 16b-3 |
In8bio Management Efficiency
The company has return on total asset (ROA) of (0.7764) % which means that it has lost $0.7764 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.8045) %, meaning that it created substantial loss on money invested by shareholders. In8bio's management efficiency ratios could be used to measure how well In8bio manages its routine affairs as well as how well it operates its assets and liabilities. As of November 27, 2024, Return On Tangible Assets is expected to decline to -0.93. In addition to that, Return On Capital Employed is expected to decline to -1.12. At present, In8bio's Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 687.7 K, whereas Total Assets are forecasted to decline to about 25.1 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Sridhar Vaddeboina | Wave Life Sciences | N/A | |
| DVM MS | Lantern Pharma | N/A | |
| Waldemar Priebe | Cns Pharmaceuticals | N/A | |
| Natalia PerezCarmona | Gain Therapeutics | N/A | |
| Evgeny Valdman | PolyPid | N/A | |
| Laxminarayan Bhat | Reviva Pharmaceuticals Holdings | 59 | |
| Claus Pedersen | Allarity Therapeutics | 52 | |
| Kenneth MD | Cue Biopharma | 64 | |
| MD FAAAAI | Palisade Bio | N/A | |
| AnneMarie LiKwaiCheung | Wave Life Sciences | N/A | |
| Narayan Prabhu | Reviva Pharmaceuticals Holdings | 52 | |
| Mirella Toro | Annexon | N/A | |
| Kirk Coleman | Tff Pharmaceuticals | 50 | |
| Steen Knudsen | Allarity Therapeutics | 63 | |
| Salvatore Calabrese | Gain Therapeutics | 54 | |
| CPA CTP | Cns Pharmaceuticals | 44 | |
| Jennifer Lew | Annexon | 51 | |
| John CPA | Windtree Therapeutics | 60 | |
| Anthony Hickey | Tff Pharmaceuticals | N/A | |
| Malka Reichart | PolyPid | N/A | |
| Steven Almo | Cue Biopharma | 63 | |
Management Performance
| Return On Equity | -1.8 | ||||
| Return On Asset | -0.78 |
In8bio Inc Leadership Team
Elected by the shareholders, the In8bio's board of directors comprises two types of representatives: In8bio inside directors who are chosen from within the company, and outside directors, selected externally and held independent of In8bio. The board's role is to monitor In8bio's management team and ensure that shareholders' interests are well served. In8bio's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, In8bio's outside directors are responsible for providing unbiased perspectives on the board's policies.
| TaiWei Ho, President, CoFounder | ||
| Patrick CPA, CFO Secretary | ||
| William Ho, President, CoFounder | ||
| Pharm MPH, VP Communications | ||
| Trishna MD, Chief Officer | ||
| Kate Rochlin, Chief Officer | ||
| Lawrence Lamb, CoFounder VP | ||
| Kenneth LaMontagne, Sr Devel | ||
| Michael McNamara, Vice Accounting |
In8bio Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is In8bio a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.8 | ||||
| Return On Asset | -0.78 | ||||
| Current Valuation | 23.49 M | ||||
| Shares Outstanding | 72.48 M | ||||
| Shares Owned By Insiders | 21.55 % | ||||
| Shares Owned By Institutions | 46.45 % | ||||
| Number Of Shares Shorted | 1 M | ||||
| Price To Book | 2.56 X | ||||
| EBITDA | (28.5 M) | ||||
| Net Income | (30.01 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether In8bio Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of In8bio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of In8bio Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on In8bio Inc Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in In8bio Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of In8bio. If investors know In8bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about In8bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.74) | Return On Assets (0.78) | Return On Equity (1.80) |
The market value of In8bio Inc is measured differently than its book value, which is the value of In8bio that is recorded on the company's balance sheet. Investors also form their own opinion of In8bio's value that differs from its market value or its book value, called intrinsic value, which is In8bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because In8bio's market value can be influenced by many factors that don't directly affect In8bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between In8bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if In8bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, In8bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.